Noxopharm (ASX:NOX) announces novel mRNA vaccine enhancer

Biotech firm Noxopharm (ASX:NOX) has developed a new proprietary product, SOF-VACTM, which aims to make mRNA vaccines safer by reducing inflammation and potentially supporting more cost-effective manufacturing.

Developed in collaboration with the Hudson Institute of Medical Research, SOF-VACTM is based on the company's SofraTM platform and is the smallest molecule of its kind to demonstrate strong anti-inflammatory activity.

Noxopharm says the mRNA market is forecast to reach $128B by 2030, with hopes SOF-VACTM possibly having a significant impact on this field.

Its share price is up 3% at 12:50pm AEST.